Skip to main content

Why the new junior doctor contract is bad for academic medicine and the UK's economy

As a clinician and academic, I was deeply saddened to see the Secretary of State for Health impose a new contract on junior doctors. The 55,000 junior doctors in England’s NHS are perhaps the most intelligent and highly educated and trained professional group in the country. They are perfectly capable of looking at the contractual changes being put forward by the NHS and drawing their own conclusions about the implications of the new contract for them. To say that they have been ‘brainwashed’ by extremist members of the British Medical Association, as some journalists and Conservative MPs have been implying, is ludicrous.

We also continue to hear from the Secretary of State for Health, Jeremy Hunt, that he believes that these contractual changes are needed to tackle higher weekend mortality in hospitals. This is an area in which I have and members of my department have published extensively. I am therefore fully aware of the research on this topic and the serious problems with some of the statements issued by Jeremy Hunt and the Department of Health (for example, see http://goo.gl/CEab0N). The UK Statistics Authority has written to the Department of Health about this matter but this letter does not seem to have had any effect on Jeremy Hunt or his officials.

Through my clinical and academic work, I am in regular contact with many junior doctors. They are becoming increasingly disillusioned and anxious about their future. Many are considering leaving the NHS to work overseas in countries such as Australia, New Zealand or Canada. Others are considering giving up their medical careers. The UK cannot afford to lose such highly trained professionals. As well as being essential for the NHS and the delivery of healthcare in England, junior doctors are also the clinical academics and medical scientists of the future. Healthcare-related industries such as pharmaceuticals are one of the few areas where the UK is still a world-leader. The future prosperity of these industries - and the economy of the UK - will be threatened by the loss of so many highly talented professionals.

Comments

Popular posts from this blog

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...